Scandinavian ChemoTech reaching a positive outcome in FloridaWild's evaluation of vetIQure™
ChemoTech's Animal Care division Vetiqure AB has been informed that the evaluation by FloridaWild Veterinary Hospital ("FloridaWild") in Deland Florida of the Company's vetIQure™ TSE unit has been concluded with a positive outcome.
In accordance with the previously communicated schedule, and after successful treatments with the vetIQure™ TSE device, FloridaWild has completed its evaluation with a positive outcome. This means that FloridaWild will submit a request for the purchase of vetIQure™ to the veterinary hospital’s procurement department. The decision is expected to take place in the fourth quarter of 2022.
“It is very gratifying to receive this confirmation from FloridaWild and once again shows how well our technology works and is appreciated by the market. We see significant potential in the Animal Care market in the US and expect that the positive collaboration with FloridaWild will create many new business opportunities going forward.” - says Mohan Frick, CEO of Scandinavian ChemoTech AB
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
ir@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
